Individualizing treatment for patients with nasopharyngeal cancer

Cancer

Volumn 121, Issue 16, 2015, Pages 2671-2673

  Hara, Wendy ^a   Le, Quynh Thu ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEMCITABINE; MESSENGER RNA; PACLITAXEL; VIRUS DNA; DNA BINDING PROTEIN; ENDONUCLEASE;

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DNA DETERMINATION; EPSTEIN BARR VIRUS; ERCC1 GENE; GENE EXPRESSION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; NASOPHARYNX CANCER; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC THERAPY; BLOOD; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MALE; NASOPHARYNX TUMOR;

DNA, VIRAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84938751428     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29418     Document Type: Review

References (21)

1. Al-Sarraf M, LeBlanc M, Giri PG, et al., Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16: 1310-1317.
2. Chen L, Hu CS, Chen XZ, et al., Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012; 13: 163-171.
3. Lee N, Harris J, Garden AS, et al., Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225. J Clin Oncol. 2009; 27: 3684-3690.
4. Lee AW, Tung SY, Ngan RK, et al., Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials. Eur J Cancer. 2011; 47: 656-666.
5. Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC., Another way to estimate outcome of advanced nasopharyngeal carcinoma-is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys. 2004; 60: 156-164.
6. Lo YM, Chan AT, Chan LY, et al., Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000; 60: 6878-6881.
7. Lo YM, Leung SF, Chan LY, et al., Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging. Ann NY Acad Sci. 2000; 906: 99-101.
8. Lo YM, Leung SF, Chan LY, et al., Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res. 2000; 60: 2351-2355.
9. Lo YM, Chan LY, Lo KW, et al., Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999; 59: 1188-1191.
10. Hui EP, Ma BBY, Chan KCA, et al., Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer. 2015; 121: 2720-2729.
11. Chan AT, Lo YM, Zee B, et al., Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002; 94: 1614-1619.
12. Lin JC, Wang WY, Chen KY, et al., Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350: 2461-2470.
13. Le QT, Jones CD, Yau TK, et al., A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res. 2005; 11: 5700-5707.
14. Hou X, Zhao C, Guo Y, et al., Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol). 2011; 23: 28-133.
15. Wang WY, Twu CW, Chen HH, et al., Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013; 119: 963-970.
16. Le QT, Zhang Q, Cao H, et al., An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013; 19: 2208-2215.
17. Vilmar A, Sorensen JB., Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of nonsmall cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009; 64: 131-139.
18. Sun JM, Ahn MJ, Park MJ, et al., Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011; 80: 655-660.
19. Jagdis A, Phan T, Klimowicz AC, et al., Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment. Int J Radiat Oncol Biol Phys. 2013; 85: 1340-1345.
20. Olaussen KA, Dunant A, Fouret P, et al., DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355: 983-991.
21. Friboulet L, Olaussen KA, Pignon JP, et al., ERCC1 isoform expression and DNA repair in nonsmall-cell lung cancer. N Engl J Med. 2013; 368: 1101-1110.